Literature DB >> 9678490

Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides.

M Klutch1, A M Woerner, C J Marcus-Sekura, J G Levin.   

Abstract

We have generated peptide antisera against selected regions in HIV-1 and HIV-2 reverse transcriptase (RT) and integrase (IN) to investigate the specificity of determinants governing the immune response. Peptides representing homologous regions (>50%) in the N- and C-termini and central portions of these proteins were synthesized and injected into rabbits. HIV-1 and HIV-2 IN peptide antisera inhibited IN-mediated cleavage of an HIV-1 DNA oligonucleotide substrate in a 3' processing assay, while anti-RT or normal sera had no effect. None of the RT sera inhibited RT activity. In Western blots, HIV-2 antisera directed against RT or IN peptides recognized HIV-2 RT and IN proteins, respectively, as expected, but also cross-reacted with the corresponding HIV-1 proteins. By contrast, corresponding HIV-1 antisera were type-specific. In some cases, HIV-1 cross-reactive antisera could be generated by immunization with HIV-1 chimeric peptides with as few as two residues in the HIV-1 sequence changed to the corresponding HIV-2 amino acids. The finding that a type-specific response can be converted to a cross-reactive response suggests alternate strategies for developing new diagnostic reagents which detect HIV-1 and HIV-2. In addition, our results provide a general model for generating HIV peptide vaccines with dual specificity against HIV-1 and HIV-2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678490     DOI: 10.1007/bf02253469

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  6 in total

1.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.

Authors:  Jiyang Jiang; Sherimay D Ablan; Suchitra Derebail; Kamil Hercík; Ferri Soheilian; James A Thomas; Shixing Tang; Indira Hewlett; Kunio Nagashima; Robert J Gorelick; Eric O Freed; Judith G Levin
Journal:  Virology       Date:  2011-10-26       Impact factor: 3.616

3.  A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein.

Authors:  Shixing Tang; Sherimay Ablan; Megan Dueck; Wilfredo Ayala-López; Brenda Soto; Margaret Caplan; Kunio Nagashima; Indira K Hewlett; Eric O Freed; Judith G Levin
Journal:  Virology       Date:  2006-10-19       Impact factor: 3.616

4.  Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.

Authors:  Shixing Tang; Tsutomu Murakami; Naiqian Cheng; Alasdair C Steven; Eric O Freed; Judith G Levin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.

Authors:  Klara Post; Jianhui Guo; Kathryn J Howard; Michael D Powell; Jennifer T Miller; Amnon Hizi; Stuart F J Le Grice; Judith G Levin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation.

Authors:  Zsófia Szojka; János András Mótyán; Márió Miczi; Mohamed Mahdi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.